Artiva Biotherapeutics, Inc. filed a Form 8-K/A amendment on November 9, 2026, providing cost estimates for its previously announced wind-down of AlloNK development and workforce reduction that were unavailable at the time of the original October 27, 2026 filing.

Key Highlights

  • Contract termination costs: The company estimates $10 million to $15 million in contract termination and other costs related to discontinuation and close-out of its AlloNK clinical trials.
  • Workforce reduction costs: The company estimates $17 million to $20 million in costs related to the workforce reduction, including severance, benefits, payroll taxes, and other termination costs.
  • Workforce reduction scale: The planned reduction covers approximately 94% of the company's current employee base.
  • Completion timeline: The company expects to complete the workforce reduction in the first quarter of 2027.
  • Cost concentration: The company expects to incur a significant majority of Wind Down costs in the fourth quarter of 2026.
  • Program discontinued: The board approved discontinuation of AlloNK (AB-101), described as a non-genetically modified, allogeneic natural killer (NK) cell therapy candidate.

Artiva Discloses Wind Down Cost Estimates After Earlier Filing Left Figures Undetermined

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) filed this 8-K/A as Amendment No. 1 to its Original 8-K filed October 27, 2026, under Item 2.05, Costs Associated with Exit or Disposal Activities. According to the filing, the company was unable at the time of the original report to make a good faith estimate of the costs connected with its wind-down, and this amendment was filed solely to supply those estimates.

The filing states that the company's board of directors approved the discontinuation of AlloNK (AB-101), its non-genetically modified, allogeneic natural killer (NK) cell therapy candidate, as the company "conducts a process to explore strategic alternatives to maximize stockholder value." Connected to that decision, the board also approved a plan to reduce the workforce by approximately 94% of its current employee base, which the filing refers to collectively as the "Wind Down."

The company now estimates total Wind Down charges in the range of $27 million to $35 million across two categories: $10 million to $15 million for contract termination and clinical trial close-out costs, and $17 million to $20 million for workforce-related costs including severance, benefits, payroll taxes, and other termination costs. The filing notes that the company "may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the Wind Down." The filing identifies the cost estimates and their timing as forward-looking statements subject to assumptions, and states that actual results may differ. These forward-looking statements are the company's own and are subject to its cautionary language as described in the filing.

What Was Disclosed

Artiva Biotherapeutics amended its prior 8-K to provide estimated Wind Down costs of $10 million to $15 million in contract termination charges and $17 million to $20 million in workforce reduction costs, with the majority expected in the fourth quarter of 2026.